Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Bembenek

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
The Journal of Chemical Physics|January 18, 2006
Calculation of the surface tension of oxygen using molecular-dynamics simulationsScott D Bembenek
Journal of Chemical Information and Modeling|May 25, 2018
Determination of a Focused Mini Kinase Panel for Early Identification of Selective Kinase InhibitorsScott D Bembenek, Gavin Hirst, Taraneh Mirzadegan
Journal of Molecular Graphics & Modelling|January 3, 2006
Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophoreFrank U Axe, Scott D Bembenek, Sándor Szalma
Journal of Medicinal Chemistry|April 3, 2008
Ligand binding efficiency: trends, physical basis, and implicationsCharles H Reynolds, Brett A Tounge, Scott D Bembenek
Drug Discovery Today|December 17, 2008
Ligand efficiency and fragment-based drug discoveryScott D Bembenek, Brett A Tounge, Charles H Reynolds
Bioorganic & Medicinal Chemistry Letters|May 29, 2007
The role of molecular size in ligand efficiencyCharles H Reynolds, Scott D Bembenek, Brett A Tounge
Methods in Molecular Biology (Clifton, N.J.)|May 14, 2004
A Web-based chemoinformatics system for drug discoveryScott D Bembenek, Brett A Tounge, Steven J Coats, et al.
Bioorganic & Medicinal Chemistry Letters|April 25, 2008
Dual binding site inhibitors of B-RAF kinaseRonald L Wolin, Scott D Bembenek, Jianmei Wei, et al.
Bioorganic & Medicinal Chemistry Letters|September 24, 2009
Pyrazole-based cathepsin S inhibitors with arylalkynes as P1 binding elementsMichael K Ameriks, Frank U Axe, Scott D Bembenek, et al.
Bioorganic & Medicinal Chemistry|February 6, 2008
Lead identification of acetylcholinesterase inhibitors-histamine H3 receptor antagonists from molecular modelingScott D Bembenek, John M Keith, Michael A Letavic, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
The Journal of Chemical Physics|January 18, 2006
Calculation of the surface tension of oxygen using molecular-dynamics simulationsScott D Bembenek
Journal of Chemical Information and Modeling|May 25, 2018
Determination of a Focused Mini Kinase Panel for Early Identification of Selective Kinase InhibitorsScott D Bembenek, Gavin Hirst, Taraneh Mirzadegan
Journal of Molecular Graphics & Modelling|January 3, 2006
Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophoreFrank U Axe, Scott D Bembenek, Sándor Szalma
Journal of Medicinal Chemistry|April 3, 2008
Ligand binding efficiency: trends, physical basis, and implicationsCharles H Reynolds, Brett A Tounge, Scott D Bembenek
Drug Discovery Today|December 17, 2008
Ligand efficiency and fragment-based drug discoveryScott D Bembenek, Brett A Tounge, Charles H Reynolds
Bioorganic & Medicinal Chemistry Letters|May 29, 2007
The role of molecular size in ligand efficiencyCharles H Reynolds, Scott D Bembenek, Brett A Tounge
Methods in Molecular Biology (Clifton, N.J.)|May 14, 2004
A Web-based chemoinformatics system for drug discoveryScott D Bembenek, Brett A Tounge, Steven J Coats, et al.
Bioorganic & Medicinal Chemistry Letters|April 25, 2008
Dual binding site inhibitors of B-RAF kinaseRonald L Wolin, Scott D Bembenek, Jianmei Wei, et al.
Bioorganic & Medicinal Chemistry Letters|September 24, 2009
Pyrazole-based cathepsin S inhibitors with arylalkynes as P1 binding elementsMichael K Ameriks, Frank U Axe, Scott D Bembenek, et al.
Bioorganic & Medicinal Chemistry|February 6, 2008
Lead identification of acetylcholinesterase inhibitors-histamine H3 receptor antagonists from molecular modelingScott D Bembenek, John M Keith, Michael A Letavic, et al.
Pageof 3